Patents by Inventor Michael B. Mann

Michael B. Mann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OB fusion protein compositions and methods
    Patent number: 8080254
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: December 20, 2011
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
  • Methods for the treatment of thrombosis
    Patent number: 7195903
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: March 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • OB fusion protein compositions and methods
    Patent number: 7112659
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 26, 2006
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • OB fusion protein compositions and methods
    Patent number: 6936439
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: August 30, 2005
    Assignee: Amgen Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • OB fusion protein compositions and methods
    Publication number: 20040067520
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Application
    Filed: October 6, 2003
    Publication date: April 8, 2004
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • Methods for the treatment of thrombosis
    Publication number: 20030186422
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Application
    Filed: May 20, 2003
    Publication date: October 2, 2003
    Applicant: AMGEN INC., a Delaware Corporation
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • DNA molecules encoding fibrinolytically active polypeptide
    Patent number: 6617145
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: September 9, 2003
    Assignee: Amgen Inc
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • OPG FUSION PROTEIN COMPOSITIONS AND METHODS
    Publication number: 20030144187
    Abstract: The present invention relates to OPG fusion protein compositions, methods of preparation of such compositions and uses thereof. More particularly, the present invention relates to a fusion protein comprising an OPG polypeptide and an immunoglobulin FC region.
    Type: Application
    Filed: September 3, 1999
    Publication date: July 31, 2003
    Inventors: COLIN R. DUNSTAN, SCOTT K.. WOODEN, MICHAEL B. MANN
  • DNA molecules encoding fibrinolytically active polypeptide
    Publication number: 20020058322
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Application
    Filed: May 1, 2001
    Publication date: May 16, 2002
    Applicant: Amgen Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • Fibronolytically active polypeptide
    Patent number: 6261820
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: July 17, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann